Search results: Sage Journals

Restricted accessResearch articleFirst published April, 2001

Prevalence and characteristics of breakthrough pain in patients with non-malignant terminal disease admitted to a hospice

Giovambattista Zeppetella, Catherine A O'Doherty, Silke Collins

Palliative Medicine

Free accessResearch articleFirst published March, 2016

Fludarabine add-on therapy in interferon-beta-treated patients with multiple sclerosis experiencing breakthrough disease

Steven J. Greenberg, Robert Zivadinov, Peterkin Lee-Kwen [...]

Therapeutic Advances in Neurological Disorders

Open accessResearch articleFirst published 2023

SARS-CoV-2 breakthrough infections after COVID-19 vaccination in patients with inflammatory bowel disease: a systematic review and meta-analysis

Natasja van de Pol, Qiuwei Pan, Lauranne A. A. P. Derikx [...]

Therapeutic Advances in Gastroenterology

Restricted accessResearch articleFirst published November, 2022

Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies

Irene Schiavetti, Cinzia Cordioli, Maria Laura Stromillo [...]

Multiple Sclerosis Journal

Restricted accessResearch articleFirst published November, 2008

Canadian treatment optimization recommendations (TOR) as a predictor of disease breakthrough in patients with multiple sclerosis treated with interferon β-1a: analysis of the PRISMS study

MS Freedman, FG Forrestal

Multiple Sclerosis Journal

Free accessResearch articleFirst published January, 2017

Adrenocorticotropic hormone versus methylprednisolone added to interferon β in patients with multiple sclerosis experiencing breakthrough disease: a randomized,rater-blinded trial

Regina Berkovich, Rohit Bakshi, Lilyana Amezcua [...]

Therapeutic Advances in Neurological Disorders

Restricted accessReview articleFirst published February, 2026

Tumor Necrosis Factor: A Master Regulator in Inflammation and Disease—Pathways,Implications,and Breakthrough Therapies

Simhadri Goud Gundrathi, Bharat Kumar Reddy Sanapalli, Ashwini Deshpande [...]

Journal of Interferon & Cytokine Research

Open accessResearch articleFirst published 2025

Longitudinal quantification of serum SARS-CoV-2 neutralising antibodies,pro-inflammatory cytokines,NfL and GFAP before and after breakthrough COVID-19 infection in CNS neuroimmunological diseases: a prospective observational study

M. Hema Prashaad, Rachel Wan En Siew, Amelia Yun Yi Aw [...]

Therapeutic Advances in Infectious Disease

Restricted accessOtherFirst published September, 2019

Breakthrough to Bedside: Bringing Gene Therapy to Neuromuscular Diseases: An Interview with Dr. Jerry R. Mendell

James M. Wilson

Human Gene Therapy Clinical Development

Open accessReview articleFirst published 2026

Collaborative action for biomarker breakthroughs: Validating α-synuclein seed amplification assays in Parkinson's disease

Luis MA Oliveira, Mark Frasier, Samantha J Hutten

Journal of Parkinson’s Disease

Restricted accessResearch articleFirst published April, 2001

Prevalence and characteristics of breakthrough pain in patients with non-malignant terminal disease admitted to a hospice

Giovambattista Zeppetella, Catherine A O'Doherty, Silke Collins

Palliative Medicine

Free accessResearch articleFirst published March, 2016

Fludarabine add-on therapy in interferon-beta-treated patients with multiple sclerosis experiencing breakthrough disease

Steven J. Greenberg, Robert Zivadinov, Peterkin Lee-Kwen [...]

Therapeutic Advances in Neurological Disorders

Open accessResearch articleFirst published 2023

SARS-CoV-2 breakthrough infections after COVID-19 vaccination in patients with inflammatory bowel disease: a systematic review and meta-analysis

Natasja van de Pol, Qiuwei Pan, Lauranne A. A. P. Derikx [...]

Therapeutic Advances in Gastroenterology

Restricted accessResearch articleFirst published November, 2022

Breakthrough SARS-CoV-2 infections in MS patients on disease-modifying therapies

Irene Schiavetti, Cinzia Cordioli, Maria Laura Stromillo [...]

Multiple Sclerosis Journal

Restricted accessResearch articleFirst published November, 2008

Canadian treatment optimization recommendations (TOR) as a predictor of disease breakthrough in patients with multiple sclerosis treated with interferon β-1a: analysis of the PRISMS study

MS Freedman, FG Forrestal

Multiple Sclerosis Journal

Free accessResearch articleFirst published January, 2017

Adrenocorticotropic hormone versus methylprednisolone added to interferon β in patients with multiple sclerosis experiencing breakthrough disease: a randomized,rater-blinded trial

Regina Berkovich, Rohit Bakshi, Lilyana Amezcua [...]

Therapeutic Advances in Neurological Disorders

Restricted accessReview articleFirst published February, 2026

Tumor Necrosis Factor: A Master Regulator in Inflammation and Disease—Pathways,Implications,and Breakthrough Therapies

Simhadri Goud Gundrathi, Bharat Kumar Reddy Sanapalli, Ashwini Deshpande [...]

Journal of Interferon & Cytokine Research

Open accessResearch articleFirst published 2025

Longitudinal quantification of serum SARS-CoV-2 neutralising antibodies,pro-inflammatory cytokines,NfL and GFAP before and after breakthrough COVID-19 infection in CNS neuroimmunological diseases: a prospective observational study

M. Hema Prashaad, Rachel Wan En Siew, Amelia Yun Yi Aw [...]

Therapeutic Advances in Infectious Disease

Restricted accessOtherFirst published September, 2019

Breakthrough to Bedside: Bringing Gene Therapy to Neuromuscular Diseases: An Interview with Dr. Jerry R. Mendell

James M. Wilson

Human Gene Therapy Clinical Development

Open accessReview articleFirst published 2026

Collaborative action for biomarker breakthroughs: Validating α-synuclein seed amplification assays in Parkinson's disease

Luis MA Oliveira, Mark Frasier, Samantha J Hutten

Journal of Parkinson’s Disease